Literature DB >> 15832538

Methadone treatment for pain states.

James D Toombs1, Lee A Kral.   

Abstract

Methadone is a synthetic opioid with potent analgesic effects. Although it is associated commonly with the treatment of opioid addiction, it may be prescribed by licensed family physicians for analgesia. Methadone's unique pharmacokinetics and pharmacodynamics make it a valuable option in the management of cancer pain and other chronic pain, including neuropathic pain states. It may be an appropriate replacement for opioids when side effects have limited further dosage escalation. Metabolism of and response to methadone varies with each patient. Transition to methadone and dosage titration should be completed slowly and with frequent monitoring. Conversion should be based on the current daily oral morphine equivalent dosage. After starting methadone therapy or increasing the dosage, systemic toxicity may not become apparent for several days. Some medications alter the absorption or metabolism of methadone, and their concurrent use may require dosing adjustments. Methadone is less expensive than other sustained-release opioid formulations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15832538

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  24 in total

1.  Applying legal risk management to the clinical use of methadone.

Authors:  James O'Donnell; F Randy Vogenberg
Journal:  P T       Date:  2011-12

2.  Tell-Tale SNPs: The Role of CYP2B6 in Methadone Fatalities.

Authors:  Taha Ahmad; Samie Sabet; Donald A Primerano; Lauren L Richards-Waugh; Gary O Rankin
Journal:  J Anal Toxicol       Date:  2017-05-01       Impact factor: 3.367

3.  Patient-controlled analgesia at the end of life at a pediatric oncology institution.

Authors:  Doralina L Anghelescu; Jennifer M Snaman; Luis Trujillo; April D Sykes; Y Yuan; Justin N Baker
Journal:  Pediatr Blood Cancer       Date:  2015-03-27       Impact factor: 3.167

4.  Imaging of subacute blood-brain barrier disruption after methadone overdose.

Authors:  Branko N Huisa; Charles Gasparovic; Saeid Taheri; Jillian L Prestopnik; Gary A Rosenberg
Journal:  J Neuroimaging       Date:  2011-12-30       Impact factor: 2.486

5.  White opioids: Pharmaceutical race and the war on drugs that wasn't.

Authors:  Julie Netherland; Helena Hansen
Journal:  Biosocieties       Date:  2017-06-28

Review 6.  Pharmacogenomics of methadone: a narrative review of the literature.

Authors:  Senthil Packiasabapathy; Blessed W Aruldhas; Nicole Horn; Brian R Overholser; Sara K Quinney; Janelle S Renschler; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2020-07-24       Impact factor: 2.533

Review 7.  Pediatric Oncology: Managing Pain at the End of Life.

Authors:  Jennifer M Snaman; Justin N Baker; Jennifer H Ehrentraut; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 8.  Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics.

Authors:  Taha Ahmad; Monica A Valentovic; Gary O Rankin
Journal:  Biochem Pharmacol       Date:  2018-02-16       Impact factor: 5.858

9.  The effect of oral methadone on the QTc interval in advanced cancer patients: a prospective pilot study.

Authors:  Suresh Reddy; David Hui; Badi El Osta; Maxine de la Cruz; Paul Walker; J Lynn Palmer; Eduardo Bruera
Journal:  J Palliat Med       Date:  2010-01       Impact factor: 2.947

Review 10.  Emerging Challenges to the Safe and Effective Use of Methadone for Cancer-Related Pain in Paediatric and Adult Patient Populations.

Authors:  Kyle P Edmonds; Ila M Saunders; Andrew Willeford; Toluwalase A Ajayi; Rabia S Atayee
Journal:  Drugs       Date:  2020-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.